Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors.
暂无分享,去创建一个
E. Raymond | M. D’Incalci | R. Frapolli | Richard J Buick | M. Riveiro | Lucile Astorgues-Xerri | M. Bekradda | E. Cvitkovic | J. Gormley | Paul Kerr | R. Vazquez | M. Békradda | Ramiro Vazquez
[1] J. F. Burrows,et al. Cathepsin S from both tumor and tumor‐associated cells promote cancer growth and neovascularization , 2013, International journal of cancer.
[2] E. Raymond,et al. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib , 2013, Cancer Chemotherapy and Pharmacology.
[3] E. Ingelsson,et al. Serum Cathepsin S Is Associated With Decreased Insulin Sensitivity and the Development of Type 2 Diabetes in a Community-Based Cohort of Elderly Men , 2012, Diabetes Care.
[4] J. Xu,et al. Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro. , 2012, Biochemical and biophysical research communications.
[5] K. Ng. Potential role of odanacatib in the treatment of osteoporosis , 2012, Clinical interventions in aging.
[6] J. Johnston,et al. Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. , 2012, Biochimie.
[7] J. Johnston,et al. Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity , 2011, Molecular Cancer.
[8] E. Brogi,et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.
[9] J. Johnston,et al. The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study , 2011, British Journal of Cancer.
[10] C. Scott,et al. The Emerging Relevance of the Cysteine Protease Cathepsin S in Disease , 2011 .
[11] I. Schechter,et al. Cathepsins S, B and L with aminopeptidases display β-secretase activity associated with the pathogenesis of Alzheimer’s disease , 2011, Biological chemistry.
[12] Alice Lee-Dutra,et al. Cathepsin S inhibitors: 2004 – 2010 , 2011, Expert opinion on therapeutic patents.
[13] J. Johnston,et al. Antibody Targeting of Cathepsin S Inhibits Angiogenesis and Synergistically Enhances Anti-VEGF , 2010, PloS one.
[14] John J. M. Wiener,et al. Recent advances in the design of cathepsin S inhibitors. , 2010, Current topics in medicinal chemistry.
[15] C. Peters,et al. Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis , 2010, Oncogene.
[16] K. Clément,et al. Cathepsins in Human Obesity: Changes in Energy Balance Predominantly Affect Cathepsin S in Adipose Tissue and in Circulation , 2010 .
[17] M. Tabrizi,et al. Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease , 2010, The AAPS Journal.
[18] J. Johnston,et al. Antibody-Mediated Inhibition of Cathepsin S Blocks Colorectal Tumor Invasion and Angiogenesis , 2009, Clinical Cancer Research.
[19] J. Xu,et al. Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma. , 2009, Molecular medicine reports.
[20] I. Bièche,et al. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. , 2009, Cancer research.
[21] Yun‐Sil Lee,et al. Radiation‐induced cathepsin S is involved in radioresistance , 2009, International journal of cancer.
[22] B. Seliger,et al. CIITA versus IFN-γ induced MHC class II expression in head and neck cancer cells , 2009, Archives of Dermatological Research.
[23] A. Ray,et al. Cysteine cathepsin S as an immunomodulatory target: present and future trends , 2008, Expert opinion on therapeutic targets.
[24] O. De Wever,et al. Role of WISP-2/CCN5 in the Maintenance of a Differentiated and Noninvasive Phenotype in Human Breast Cancer Cells , 2007, Molecular and Cellular Biology.
[25] O. Vasiljeva,et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. , 2007, Current pharmaceutical design.
[26] Bonnie F. Sloane,et al. Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.
[27] P. Hamilton,et al. Cathepsin S expression: An independent prognostic factor in glioblastoma tumours—a pilot study , 2006, International journal of cancer.
[28] R. Kalluri,et al. Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors* , 2006, Journal of Biological Chemistry.
[29] Christopher M. Overall,et al. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.
[30] Jean-Daniel Zucker,et al. Cathepsin S, a novel biomarker of adiposity: relevance to atherogenesis , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[31] G. Berx,et al. The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. , 2005, Cancer research.
[32] Bonnie F. Sloane,et al. Cysteine cathepsins in human cancer , 2004, Biological chemistry.
[33] P. Johnston,et al. The clinical significance of cathepsin S expression in human astrocytomas. , 2003, The American journal of pathology.
[34] Bonnie F. Sloane,et al. Expression of cathepsins B and S in the progression of prostate carcinoma , 2001, International journal of cancer.
[35] D. Brömme,et al. Evaluation of Dipeptide α-Keto-β-aldehydes as New Inhibitors of Cathepsin S☆ , 2000 .
[36] G. Dranoff,et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. , 1999, Immunity.
[37] R. Mitchell,et al. Cathepsin S activity regulates antigen presentation and immunity. , 1998, The Journal of clinical investigation.
[38] S. Weiss,et al. Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[39] D. Selkoe,et al. The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study. , 1995, The American journal of pathology.
[40] D. Rich,et al. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. , 1992, The Journal of biological chemistry.
[41] Christopher M Overall,et al. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. , 2006, Nature reviews. Cancer.
[42] D. Brömme,et al. Evaluation of dipeptide alpha-keto-beta-aldehydes as new inhibitors of cathepsin S. , 2000, Biochemical and biophysical research communications.
[43] D. Steiner,et al. The expression of cathepsin B and other lysosomal proteinases in normal tissues and in tumors. , 1991, Biomedica biochimica acta.